Axiom Biosciences

Precision regenerative therapies for brain injury. IPO ahead

https://wefunder.com/axiombiosciences

Total raised on Wefunder: 673616

Total investors: 58

Quick facts

• First US biotech targeting Hong Kong listing at $1B+ (2027); Nasdaq at $3B+ (2029); not guaranteed
• In clinical trial for IVH (brain bleeds in newborns): mortality eliminated, from ~46% to 0%
• $21M raised from VCs like Partners Investment & Proxima Ventures & 8 grants (NIH, CIRM, DoD)
• Targeting a $16.6B annual market in the US with 7+ years of FDA market exclusivity
• 50+ patents pending and 9 issued globally
• 2 FDA Rare Pediatric Disease Designations & potential Priority Review Vouchers; est. $400M+ value
• 2 FDA Orphan Disease Designations secure 7+ years of exclusivity, protecting $4.7B in revenue
• World-class team from Stanford, Cornell, Yale, NYU & Michigan, backed by J&J Innovation Labs

Team profiles

• Remo Moomiaie
• Karen Markham
• Reem Yunis, PhD.

Featured investor profiles

• John Ballantyne, PhD
• Partners Investment
• Proxima Ventures
• Gemseki Investment
• Inventa Capital